VBIO Stock Forecast: Valion Bio, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 1 Aug 2026 — in the weakest quartile.
VBIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Valion Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Valion Bio, Inc. — and when they’d sell — is the membership.
VBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Valion Bio, Inc. (VBIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- −0.9×
Cheaper than 76% of US stocks
Cheaper than 90% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −182.2%
- Return on assets
- −36.2%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VBIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VBIO appears on the weeks it earns a place.
Frequently asked questions about VBIO stock
How does Ticker Nerd's model rank VBIO?
As at 1 Aug 2026, Valion Bio, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the VBIO stock forecast for 2030?
No analyst covering Valion Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VBIO are extrapolating price history, which says nothing about the business.
How has VBIO stock performed over the past year?
Valion Bio, Inc. returned -90.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Valion Bio, Inc. do?
Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
CEO Mr. Michael Kevin Handley · 52 employees · United States · https://valionbio.com